Andrx settles Glucotrol infringement suit
Executive Summary
Andrx agrees with Pfizer and Alza to settle patent infringement litigation over the company's ANDA for a generic version of Glucotrol XL (glipizide extended release). All claims were dropped with Andrx agreeing to receive a royalty-bearing sublicense under relevant Alza patents. Andrx believes it was first to file a glipizide ANDA. Andrx filed a citizen's petition with FDA related to the case in November (1"The Pink Sheet" Nov. 11, 2002, p. 25)...
You may also be interested in...
Pfizer Glucotrol XL Patent Should Be Deemed Late Listed – Andrx
FDA should deem a patent on Pfizer's Glucotrol XL "late-listed," even if it is reissued and listed in the "Orange Book," Andrx says in a 1citizen petition
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.